NMIL 12 1

Drug Profile

NMIL 12 1

Alternative Names: HemaMax; NM-IL-12; NMIL12-1; Recombinant-human-interleukin-12 - Neumedicines; Recombinant-interleukin-12 - Neumedicines; rHu-IL12; rHuIL-12 – Neumedicines

Latest Information Update: 08 Feb 2017

Price : $50

At a glance

  • Originator Neumedicines
  • Class Interleukins; Recombinant proteins
  • Mechanism of Action Angiogenesis inhibitors; Immunostimulants; Interferon gamma stimulants; Macrophage stimulants; Natural killer cell stimulants; T lymphocyte stimulants; Tumour necrosis factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute radiation syndrome; Cutaneous T cell lymphoma; Wound infections
  • Preclinical Acute myeloid leukaemia; Malignant melanoma; Solid tumours
  • No development reported Pancytopenia

Most Recent Events

  • 03 Dec 2016 Adverse events, efficacy, pharmacodynamics and pharmacokinetics data presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
  • 03 Dec 2016 Neumedicines plans a phase IIB trial for Cutaneous T-cell lymphoma
  • 18 Jul 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top